Toll Free Helpline (India): 1800 1234 070
Rest of World: +91-9810852116
Free Publication Certificate
Submit Manuscript
Journal code(s)
- E-ISSN Number: 2277-7695
- P-ISSN Number: 2349-8242
- CODEN Code: PIHNBQ
- ZDB-Number: 2663038-2
- IC Journal ID: 7725
Main Menu
Special Issue
Copyright Form
Identifier
Vol. 3, Issue 9 (2014)
Statin use enhances parasitological response to quinine against falciparum malaria
Author(s):
Ndubuisi N. Nwobodo, Paul O. Okonkwo, Samuel A. Igwe
Ndubuisi N. Nwobodo, Paul O. Okonkwo, Samuel A. Igwe
Abstract:
Antimalarial drug resistance to quinine may result from either changes in drug accumulation or efflux leading to reduced intra-parasitic concentrations of the drug. The study examines the effects of simvastatin in modulating parasitological response to quinine. Subjects with clinically characterized malaria (n=60) confirmed by thick blood film and immunological tests, were categorized into test and control groups after obtaining informed consent. Ethical clearance certification was obtained from the University of Nigeria Teaching Hospital Research Ethics Committee (NHREC/05/01/2008B). The test (quinine + simvastatin) group received oral quinine and simvastatin, while the control (quinine alone) group received only quinine. The subjects were followed up on days D0, D3, D7, D14 and D28 post-treatment. The assessment of clinical response was carried out in line with WHO criteria. GraphPad Prism 4.0 was employed in the analysis of data. Statistical test of significance between test and control groups determined using two-tailed Student t-test, p<0.05 considered as significant and data presented in tabular and graphical forms. A statistically significant difference in parasitological response was reported between test and control groups (*p<0.05). The value of low level resistance, RI was given as 2.4±0.17%, mid-level resistance RII as 3.9±0.25%, high level parasitological resistance, RIII as 3.1±0.26% and the late parasitological failure (LPF) as 3.7±0.46% in the test group. The consideration of LPF alongside gives an overall parasitological resistance of 13.1±0.88% in the test group. This contrasts with the value of RI given as 12.2±0.56%, RII as 13.7±0.48%, RIII as 4.9±0.18% and the LPF given as 4.5.6±0.16% in the control group. Again, the consideration of LPF alongside gives an overall parasitological resistance of 35.3±01.4% in the control group. The outcome of present study lends credence to the potential role of 3-HMG-CoA reductase inhibitor, simvastatin, in combination with quinine in modulating parasitological response in the treatment of malaria.
Antimalarial drug resistance to quinine may result from either changes in drug accumulation or efflux leading to reduced intra-parasitic concentrations of the drug. The study examines the effects of simvastatin in modulating parasitological response to quinine. Subjects with clinically characterized malaria (n=60) confirmed by thick blood film and immunological tests, were categorized into test and control groups after obtaining informed consent. Ethical clearance certification was obtained from the University of Nigeria Teaching Hospital Research Ethics Committee (NHREC/05/01/2008B). The test (quinine + simvastatin) group received oral quinine and simvastatin, while the control (quinine alone) group received only quinine. The subjects were followed up on days D0, D3, D7, D14 and D28 post-treatment. The assessment of clinical response was carried out in line with WHO criteria. GraphPad Prism 4.0 was employed in the analysis of data. Statistical test of significance between test and control groups determined using two-tailed Student t-test, p<0.05 considered as significant and data presented in tabular and graphical forms. A statistically significant difference in parasitological response was reported between test and control groups (*p<0.05). The value of low level resistance, RI was given as 2.4±0.17%, mid-level resistance RII as 3.9±0.25%, high level parasitological resistance, RIII as 3.1±0.26% and the late parasitological failure (LPF) as 3.7±0.46% in the test group. The consideration of LPF alongside gives an overall parasitological resistance of 13.1±0.88% in the test group. This contrasts with the value of RI given as 12.2±0.56%, RII as 13.7±0.48%, RIII as 4.9±0.18% and the LPF given as 4.5.6±0.16% in the control group. Again, the consideration of LPF alongside gives an overall parasitological resistance of 35.3±01.4% in the control group. The outcome of present study lends credence to the potential role of 3-HMG-CoA reductase inhibitor, simvastatin, in combination with quinine in modulating parasitological response in the treatment of malaria.
Fig.: Depicts bar chart showing mean low level (RI), moderate level (RII), high level (RIII) parasitological resistance and late parasitological failure (LPF) in both test and control groups treated with quinine. A statistically significant difference (p<0.05) was reported between the test and control subjects respectively in all the above parameters assessed for parasitological response. The error bars as shown were indicative of the standard error of mean (SEM).
Pages: 17-21 | 1574 Views 73 Downloads
How to cite this article:
Ndubuisi N. Nwobodo, Paul O. Okonkwo, Samuel A. Igwe. Statin use enhances parasitological response to quinine against falciparum malaria. Pharma Innovation 2014;3(9):17-21.
Journal code(s)
- E-ISSN Number: 2277-7695
- P-ISSN Number: 2349-8242
- CODEN Code: PIHNBQ
- ZDB-Number: 2663038-2
- IC Journal ID: 7725
Main Menu
Special Issue
Copyright Form
Identifier
The Pharma Innovation Journal
